AIMS: To evaluate the pharmacokinetic interactions between ritonavir and quinine in healthy volunteers. METHODS: Ten healthy volunteers were each given 600-mg single oral doses of quinine alone, ritonavir alone (200 mg every 12 h for 9 days), and quinine in combination with ritonavir, in a three-period pharmacokinetic nonrandomized sequential design study. Quinine was co-administered with the 15th dose of ritonavir. Blood samples collected at predetermined time intervals were analysed for ritonavir, quinine and its major metabolite, 3-hydroxyquinine, using a validated high-performance liquid chromatography method. RESULTS: Concurrent ritonavir administration resulted in about fourfold increases in both the C(max) and AUC(T)[C(max) 2.79 +/- 0.22 vs. 10.72 +/- 0.32 mg l(-1), 95% confidence interval (CI) 7.81, 8.04; AUC 50.06 +/- 2.52 vs. 220.47 +/- 6.68 mg h(-1) l(-1), 95% CI 166.3, 175.3], a significant increase (P < 0.01) in the elimination half-life (11.15 +/- 0.80 vs. 13.37 +/- 0.33 h, 95% CI 1.64, 2.77) and about a 4.5-fold decrease in CL/F (12.01 +/- 0.61 vs. 2.71 +/- 0.09 l h(-1)) of quinine. Also, with ritonavir, there was a pronounced reduction of AUC(metabolite)/AUC(unchanged drug) ratio of quinine (1.35 +/- 0.10 vs. 0.13 +/- 0.02) along with a marked decrease in C(max) (1.80 +/- 0.12 vs. 0.96 +/- 0.09 mg l(-1)) and AUC(0-48h) (62.80 +/- 6.30 vs. 25.61 +/- 2.44 mg h(-1) l(-1)) of the metabolite. Similarly, quinine caused modest but significant increases (P < 0.01) in the C(max), AUC and elimination T((1/2)) of ritonavir. CONCLUSIONS: Downward dosage adjustment of quinine appears necessary when concurrently administered with ritonavir.
AIMS: To evaluate the pharmacokinetic interactions between ritonavir and quinine in healthy volunteers. METHODS: Ten healthy volunteers were each given 600-mg single oral doses of quinine alone, ritonavir alone (200 mg every 12 h for 9 days), and quinine in combination with ritonavir, in a three-period pharmacokinetic nonrandomized sequential design study. Quinine was co-administered with the 15th dose of ritonavir. Blood samples collected at predetermined time intervals were analysed for ritonavir, quinine and its major metabolite, 3-hydroxyquinine, using a validated high-performance liquid chromatography method. RESULTS: Concurrent ritonavir administration resulted in about fourfold increases in both the C(max) and AUC(T)[C(max) 2.79 +/- 0.22 vs. 10.72 +/- 0.32 mg l(-1), 95% confidence interval (CI) 7.81, 8.04; AUC 50.06 +/- 2.52 vs. 220.47 +/- 6.68 mg h(-1) l(-1), 95% CI 166.3, 175.3], a significant increase (P < 0.01) in the elimination half-life (11.15 +/- 0.80 vs. 13.37 +/- 0.33 h, 95% CI 1.64, 2.77) and about a 4.5-fold decrease in CL/F (12.01 +/- 0.61 vs. 2.71 +/- 0.09 l h(-1)) of quinine. Also, with ritonavir, there was a pronounced reduction of AUC(metabolite)/AUC(unchanged drug) ratio of quinine (1.35 +/- 0.10 vs. 0.13 +/- 0.02) along with a marked decrease in C(max) (1.80 +/- 0.12 vs. 0.96 +/- 0.09 mg l(-1)) and AUC(0-48h) (62.80 +/- 6.30 vs. 25.61 +/- 2.44 mg h(-1) l(-1)) of the metabolite. Similarly, quinine caused modest but significant increases (P < 0.01) in the C(max), AUC and elimination T((1/2)) of ritonavir. CONCLUSIONS: Downward dosage adjustment of quinine appears necessary when concurrently administered with ritonavir.
Authors: R B Kim; C Wandel; B Leake; M Cvetkovic; M F Fromm; P J Dempsey; M M Roden; F Belas; A K Chaudhary; D M Roden; A J Wood; G R Wilkinson Journal: Pharm Res Date: 1999-03 Impact factor: 4.200
Authors: D Ouellet; A Hsu; G R Granneman; G Carlson; J Cavanaugh; H Guenther; J M Leonard Journal: Clin Pharmacol Ther Date: 1998-10 Impact factor: 6.875
Authors: Moses R Kamya; Pauline Byakika-Kibwika; Anne F Gasasira; Diane Havlir; Philip J Rosenthal; Grant Dorsey; Jane Achan Journal: Future Virol Date: 2012 Impact factor: 1.831
Authors: Tina S Skinner-Adams; Alice S Butterworth; Kimberly A Porter; Ronald D'Amico; Fred Sawe; Doug Shaffer; Abraham Siika; Mina C Hosseinipour; Elizabeth Stringer; Judith S Currier; Tsungai Chipato; Robert Salata; Shahin Lockman; Joseph J Eron; Steven R Meshnick; James S McCarthy Journal: PLoS One Date: 2012-04-03 Impact factor: 3.240
Authors: Jane Achan; Ambrose O Talisuna; Annette Erhart; Adoke Yeka; James K Tibenderana; Frederick N Baliraine; Philip J Rosenthal; Umberto D'Alessandro Journal: Malar J Date: 2011-05-24 Impact factor: 2.979
Authors: Charlotte V Hobbs; Saurabh Dixit; Scott R Penzak; Tejram Sahu; Sachy Orr-Gonzalez; Lynn Lambert; Katie Zeleski; Jingyang Chen; Jillian Neal; William Borkowsky; Yimin Wu; Patrick E Duffy Journal: PLoS One Date: 2014-12-26 Impact factor: 3.240
Authors: Sanna R Rijpma; Jeroen J M W van den Heuvel; Maarten van der Velden; Robert W Sauerwein; Frans G M Russel; Jan B Koenderink Journal: Malar J Date: 2014-09-13 Impact factor: 2.979